AACR 2022 | Combinatorial PARPi therapies in advanced endometrial cancer

Benoit You, MD, PhD, Centre Hospitalier Lyon-Sud, Saint-Genis-Laval, France, discusses potential PARP inhibition based combinatorial therapies for endometrial cancer (EC) following the recent success of similar strategies in ovarian cancer which shares pathological features with EC such as defective homologous recombination. PARP inhibition is being evaluated as a maintenance therapy following chemotherapy and in combination with immunotherapy or anti-angiogenic medicines. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.